BioCryst to sell European Orladeyo business

28 June 2025

North Carolina, USA-based biotech BioCryst Pharmaceuticals (Nasdaq: BCRX) on Friday announced it has signed a definitive agreement to sell its European Orladeyo (berotralstat) business to Italy’s Neopharmed Gentili for up to $264 million.

BioCryst, whose shares dipped more than 3% to $9.36 on the news, plans to use the proceeds from the transaction to retire all remaining term debt ($249 million) from Pharmakon, which will eliminate around $70 million of future interest payments. The company now expects to end 2027 with approximately $700 million in cash and no term debt. This represents an increase of $400 million to prior 2027 net cash guidance.

Orladeyo is marketed for the prevention of recurrent attacks of hereditary angioedema (HAE: rapid swelling under the skin). The drug generated net revenue in the first quarter of 2025 of $134.2 million (+51% year-over-year).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology